Final data from the phase III VALOR trial and its open-label extension study showed that patients with SOD1-mutated ALS benefit from treatment with the intrathecal antisense oligonucleotide tofersen.
Reduced renal function significantly alters blood biomarkers of neurodegeneration but acts as a disease modifier rather than an independent risk factor for dementia.
A bureaucratic showdown over North Carolina’s certificate-of-need laws has stalled a critical hospital project, straining care in the state’s mountain communities.